Lv31
314 积分 2026-01-05 加入
Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
31分钟前
已完结
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies
1小时前
已完结
Adjuvant Therapy of Colon Cancer: Current Status and Future Directions
1小时前
已完结
ERO1α regulates colon cancer progression and 5-FU resistance through the miR-451a/ARF1 axis
1小时前
已完结
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells
1小时前
已完结
KLF6-mediated recruitment of the p300 complex enhances H3K23su and cooperatively upregulates SEMA3C with FOSL2 to drive 5-FU resistance in colon cancer cells
1小时前
已完结
Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway
1小时前
已完结
Impressive Suppression of Colon Cancer Growth by Triple Combination SN38/EF24/Melatonin: “Oncogenic” Versus “Onco-Suppressive” Reactive Oxygen Species
1小时前
已完结
Clinical Updates for Colon Cancer Care in 2022
1小时前
已完结
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
1个月前
已完结
皖公网安备34019202002308
